| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|---|---|---|---|---|---|
Related Party Transaction | ||||||
Related Party Transaction | ||||||
Roche [Member] | ||||||
Product and Service | ||||||
Product and Service | ||||||
Molecular Information Services [Member] | ||||||
Pharma Research and Development Services [Member] | ||||||
Revenue: | ||||||
Revenue | ||||||
- | - | - | 60,221 | 28,136 | - | - |
Related-party revenue | ||||||
- | - | - | 858 | 854 | - | - |
Total revenue | ||||||
152,903 | 116,865 | 93,203 | 61,079 | 28,990 | 10,645 | 2,057 |
Costs and expenses: | ||||||
Cost of molecular information services | ||||||
- | - | - | 27,434 | 11,659 | 5,681 | 258 |
Selling and marketing | ||||||
66,727 | 57,951 | 49,030 | 28,997 | 12,326 | 3,454 | 1,555 |
General and administrative | ||||||
70,340 | 48,611 | 50,614 | 27,302 | 21,865 | 8,644 | 6,992 |
Research and development | ||||||
91,509 | 67,371 | 43,883 | 30,629 | 24,901 | 14,777 | 9,023 |
Total costs and expenses | ||||||
313,846 | 230,681 | 182,958 | 114,362 | 70,751 | 32,556 | 17,828 |
Loss from operations | ||||||
-160,943 | -113,816 | -89,755 | -53,283 | -41,761 | -21,911 | -15,771 |
Interest (expense) income, net | ||||||
-727 | 624 | 124 | -42 | -235 | -421 | -421 |
Other income | ||||||
204 | - | - | 1,103 | -948 | -61 | -845 |
Total other income (expense), net | ||||||
- | - | - | 1,061 | -1,183 | -482 | -1,266 |
Net loss | ||||||
-161,466 | -113,192 | -89,631 | -52,222 | -42,944 | -22,393 | -17,037 |
Other comprehensive (loss)/income: | ||||||
Unrealized gain/(loss) on available-for-sale securities | ||||||
9 | 169 | -178 | - | - | - | - |
Foreign currency translation adjustment | ||||||
114 | -5 | - | - | - | - | - |
Total other comprehensive (loss)/income | ||||||
123 | 164 | -178 | - | - | - | - |
Comprehensive loss | ||||||
-161,343 | -113,028 | -89,809 | -52,222 | -42,944 | -22,393 | -17,037 |
Net loss | ||||||
-161,466 | -113,192 | -89,631 | - | -42,944 | -22,393 | -17,037 |
Accretion of redeemable convertible preferred stock | ||||||
- | - | - | - | 139 | 286 | 296 |
Net loss applicable to common stockholders | ||||||
- | - | - | - | -43,083 | -22,679 | -17,333 |
Net loss per common share, basic and diluted | ||||||
-4.50 | -3.25 | -2.73 | -1.87 | -4.64 | -10.47 | -14.06 |
Weighted-average common shares outstanding, basic and diluted | ||||||
35,877 | 34,794 | 32,836 | 27,954 | 9,294 | 2,166 | 1,232 |